Previous 10 | Next 10 |
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial (IO...
Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technolog...
2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...
2023-06-14 13:15:45 ET Gainers: WeTrade Group ( WETG ) +81% . SEALSQ Corp ( LAES ) +81% . Greenidge Generation Holdings ( GREE ) +49% . NextDecade Corporation ( NEXT ) +45% . WiSA Technologies ( WISA ) +31% . Vera Therapeutic...
2023-06-14 10:03:06 ET Gainers: Inventiva ( IVA ) +25% . Gossamer Bio ( GOSS ) +21% . Akoya Biosciences ( AKYA ) +19% . InVivo Therapeutics ( NVIV ) +14% . Bone Biologics ( BBLG ) +13% . Losers: IO Biotech ( IOBT ...
2023-06-14 08:32:02 ET Advanced Health Intelligence ( AHI ) -25% . Eastside Distilling ( EAST ) -24% on plans for exchanging debt for equity with lenders . Coeptis Therapeutics Holdings ( COEP ) -21% . IperionX Limited ( IPX ) -16% . IO ...
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized Data obtained...
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP,...
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, a...
2023-05-11 17:25:15 ET IO Biotech press release ( NASDAQ: IOBT ): Q1 GAAP EPS of -$0.59 beats by $0.09 . For further details see: IO Biotech GAAP EPS of -$0.59 beats by $0.09
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and ...